Evidence map›Paper›PMID 34061023›Full record

ArticleeLife2021

Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link.

Huyen Nguyen, Christian Wandell Thorball, Jacques Fellay, Jürg Böni, Sabine Yerly, Matthieu Perreau, Hans H Hirsch, Katharina Kusejko, Maria Christine Thurnheer, Manuel Battegay and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Huyen NguyenDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1486-8970
Christian Wandell ThorballSchool of Life Sciences, École Polytechnique, Fédérale de Lausanne, Switzerland.
Jacques FellaySchool of Life Sciences, École Polytechnique, Fédérale de Lausanne, Switzerland.ORCID 0000-0002-8240-939X
Jürg BöniInstitute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland.
Sabine YerlyLaboratory of Virology, Geneva University Hospital, University of Geneva, Geneva, Switzerland.
Matthieu PerreauDivision of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
Hans H HirschTransplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Katharina KusejkoDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4638-1940
Maria Christine ThurnheerUniversity Clinic of Infectious Diseases, University Hospital of Bern, University of Bern, Bern, Switzerland.
Manuel BattegayInfectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Matthias CavassiniDepartment of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Christian R KahlertDivision of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.ORCID 0000-0002-0784-3276
Enos BernasconiDivision of Infectious Diseases, Regional Hospital, Lugano, Switzerland.
Huldrych F GünthardDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Roger D KouyosDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-9220-8348
Swiss HIV Cohort Study
University of Zurich · CHÉcole Polytechnique Fédérale de Lausanne · CHKantonsspital St. Gallen · CHOspedale regionale di Lugano · CHUniversity Hospital of Basel · CHUniversity Hospital of Lausanne · CHUniversity of Basel · CHUniversity of Bern · CHUniversity of Geneva · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Considering the remaining threat of drug-resistantmutations (DRMs) to antiretroviral treatment (ART) efficacy, we investigated how the selective pressure of human leukocyte antigen (HLA)-restricted cytotoxic T lymphocytes drives certain DRMs' emergence and retention. Methods: We systematically screened DRM:HLA class I allele combinations in 3997 ART-naïve Swiss HIV Cohort Study (SHCS) patients. For each pair, a logistic regression model preliminarily tested for an association with the DRM as the outcome. The three HLA:DRM pairs remaining after multiple testing adjustment were analyzed in three ways: cross-sectional logistic regression models to determine any HLA/infection time interaction, survival analyses to examine if HLA type correlated with developing specific DRMs, and via NetMHCpan to find epitope binding evidence of immune escape. Results: Only one pair, RT-E138:HLA-B18, exhibited a significant interaction between infection duration and HLA. The survival analyses predicted two pairs with an increased hazard of developing DRMs: RT-E138:HLA-B18 and RT-V179:HLA-B35. RT-E138:HLA-B18 exhibited the greatest significance in both analyses (interaction term odds ratio [OR] 1.169 [95% confidence interval (CI) 1.075-1.273]; p-value<0.001; survival hazard ratio 12.211 [95% CI 3.523-42.318]; p-value<0.001). The same two pairs were also predicted by netMHCpan to have epitopic binding. Conclusions: We identified DRM:HLA pairs where HLA presence is associated with the presence or emergence of the DRM, indicating that the selective pressure for these mutations alternates direction depending on the presence of these HLA alleles. Funding: Funded by the Swiss National Science Foundation within the framework of the SHCS, and the University of Zurich, University Research Priority Program: Evolution in Action: From Genomes Ecosystems, in Switzerland.

Indexed as

Genome, HumanGenome, ViralMutationAnti-Retroviral AgentsCross-Sectional StudiesDrug Resistance, ViralFemaleHIV InfectionsHLA AntigensHumansLongitudinal StudiesMaleMiddle AgedMutation RateProspective StudiesRisk AssessmentAnti-Retroviral AgentsHLA Antigensepidemiologyglobal healthHIVHLAhumaninfectious diseasemicrobiologymutations

Identifiers

PMID34061023
PMCPMC8169104
OpenAlexW3165559855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.